Our core commitment centers on advancing R and D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors. These therapies offer promising avenues for enhancing treatment methodologies, thereby fostering optimism for improved outcomes among patients grappling with these challenging conditions.

The recent submission of a Biologics License Application (BLA) by Adaptimmune is a remarkable milestone, signifying remarkable progress in gaining regulatory approval for their TCR-based cancer therapy. This achievement indicates a pivotal step forward, paving the way for broader accessibility of this innovative treatment to patients in critical need.

The 5th TCR-based Therapies for Solid Tumors Summit returns as your only meeting where TCR pipelines have the center stage, serving as your ultimate platform to network with the most senior industry leaders in biopharma dedicated to accelerating clinical and commercial development of TCR-based therapeutics.

URLs:

Tickets: https://go.evvnt.com/2147535-2?pid=91 

Brochure: https://go.evvnt.com/2147535-3?pid=91 

Prices:

Drug Developer Pricing - Conference + Workshop Day - On the Door: USD 4197.00,

Drug Developer Pricing - Conference Only - On the Door: USD 2999.00,

Standard Pricing - Conference + Workshop Day - On the Door: USD 5097.00,

Standard Pricing - Conference Only - On the Door: USD 3699.00,

Academic Pricing - Conference + Workshop Day - On the Door: USD 3597.00,

Academic Pricing - Conference Only - On the Door: USD 2599.00

Speakers: Alfred Lim, Head of Pipeline Research, Etcembly, Andrew Bayliffe, Chief Scientific Officer, Marengo Therapeutics, Cagan Gurer, Vice President Disovery, TScan Therapeutics, Casey Bermack, Oncology Fellow, MD Anderson Cancer Center, Cassian Yee, Professor, Department of Immunology and Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Chengbin Wu, Chief Executive Officer, EpiMab, Dan MacLeod, Vice President - Discovery, Immunoscape, David Dilillo, Senior Director, Immuno-Oncology, Regeneron, Debora Barton, Chief Medical Officer, TScan Therapeutics, E-Chiang Lee, Executive Vice President - Research, T Therapeutics, Gavin MacBeath, Chief Executive Officer, TScan Therapeutics, Geraldine Paulus, Co-Founder, Vice President of Corporate Development and Operations, Crossbow Technology, Hubert Lam, Vice President - Preclinical Development, Affini-T Therapeutics, Inan Edes, Scientist and Co-Founder, Chief Executive Officer, Captain T Cell, Kenneth LaMontagne, Chief Business Officer, Zelluna Immunotherapy, Leonardo Borras, Chief Scientific Officer, CDR Life, Michael Lehmicke, Senior Vice President, Science and Industry Affairs, Alliance for Regenerative Medicine, Michael Platten, Co-Founder, TcellTech, Peggy Sotiropoulou, Chief Scientific Officer, T-knife Therapeutics, Reagan Jarvis, Chief Executive Officer, Anocca, Richard Harbottle, Head of DNA Vector Research Group, DKFZ, Rodrigo Vazquez-Lombardi, Chief Scientific Officer, Engimmune, Scott Norberg, Head of Solid Tumor Therapy Group, National Cancer Institute (NCI), Shannon Oda, Principal Investigator, Seattle Children's Hospital, Shawn P Kubli, Co-Founder, Director of Cell Therapy, Treadwell Therapeutics, Stewart Abbot, Chief Scientific Officer, Turnstone Therapeutics, Thomas Andresen, Chief Executive Officer, T-Cypher Bio, Wendell Yang, President and Founder, Imgen BioSciences, Yanyan Han, Chief Scientific Officer, HRYZ, Zhen Su, Chief Executive Officer, Marengo Therapeutics